Literature DB >> 15070938

Dichloroacetate therapy attenuates the blood lactate response to submaximal exercise in patients with defects in mitochondrial energy metabolism.

G E Duncan1, L A Perkins, D W Theriaque, R E Neiberger, P W Stacpoole.   

Abstract

We determined acute and chronic effects of dichloroacetate (DCA) on maximal (MAX) and submaximal (SUB) exercise responses in patients with abnormal mitochondrial energetics. Subjects (n = 9) completed a MAX treadmill bout 1 h after ingesting 25 mg/kg DCA or placebo (PL). A 15-min SUB bout was completed the next day while receiving the same treatment. After a 1-d washout, MAX and SUB were repeated while receiving the alternate treatment (acute). Gas exchange and heart rate were measured throughout all tests. Blood lactate (Bla) was measured 0, 3, and 10 min after MAX, and 5, 10, and 15 min during SUB. MAX and SUB were repeated after 3 months of daily DCA or PL. After a 2-wk washout, a final MAX and SUB were completed after 3 months of alternate treatment (chronic). Average Bla during SUB was lower (P < 0.05) during both acute (1.99 +/- 1.10 vs. 2.49 +/- 1.52 mmol/liter) and chronic (1.71 +/- 1.37 vs. 2.39 +/- 1.32 mmol/liter) DCA vs. PL despite similar exercise intensities between conditions ( approximately 75 and 70% maximal exercise capacity during acute and chronic treatment). Thus, although DCA does not alter MAX responses, acute and chronic DCA attenuate the Bla response to moderate exercise in patients with abnormal mitochondrial energetics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15070938     DOI: 10.1210/jc.2003-031684

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

Review 1.  The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients.

Authors:  Kavi P Patel; Thomas W O'Brien; Sankarasubramon H Subramony; Jonathan Shuster; Peter W Stacpoole
Journal:  Mol Genet Metab       Date:  2011-10-07       Impact factor: 4.797

Review 2.  Mitochondrial medicine: to a new era of gene therapy for mitochondrial DNA mutations.

Authors:  Hélène Cwerman-Thibault; José-Alain Sahel; Marisol Corral-Debrinski
Journal:  J Inherit Metab Dis       Date:  2010-06-23       Impact factor: 4.982

3.  The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients.

Authors:  Kavi P Patel; Thomas W O'Brien; Sankarasubramon H Subramony; Jonathan Shuster; Peter W Stacpoole
Journal:  Mol Genet Metab       Date:  2012-07       Impact factor: 4.797

4.  Why are there no proven therapies for genetic mitochondrial diseases?

Authors:  Peter W Stacpoole
Journal:  Mitochondrion       Date:  2011-05-13       Impact factor: 4.160

5.  Long-term safety of dichloroacetate in congenital lactic acidosis.

Authors:  Monica Abdelmalak; Alicia Lew; Ryan Ramezani; Albert L Shroads; Bonnie S Coats; Taimour Langaee; Meena N Shankar; Richard E Neiberger; S H Subramony; Peter W Stacpoole
Journal:  Mol Genet Metab       Date:  2013-04-06       Impact factor: 4.797

Review 6.  The elusive magic pill: finding effective therapies for mitochondrial disorders.

Authors:  Amy Goldstein; Lynne A Wolfe
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

Review 7.  Role of dichloroacetate in the treatment of genetic mitochondrial diseases.

Authors:  Peter W Stacpoole; Tracie L Kurtz; Zongchao Han; Taimour Langaee
Journal:  Adv Drug Deliv Rev       Date:  2008-07-04       Impact factor: 15.470

Review 8.  Treatment for mitochondrial disorders.

Authors:  Gerald Pfeffer; Kari Majamaa; Douglass M Turnbull; David Thorburn; Patrick F Chinnery
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

Review 9.  Current and Emerging Clinical Treatment in Mitochondrial Disease.

Authors:  Rory J Tinker; Albert Z Lim; Renae J Stefanetti; Robert McFarland
Journal:  Mol Diagn Ther       Date:  2021-03-01       Impact factor: 4.074

Review 10.  New treatments for mitochondrial disease-no time to drop our standards.

Authors:  Gerald Pfeffer; Rita Horvath; Thomas Klopstock; Vamsi K Mootha; Anu Suomalainen; Saskia Koene; Michio Hirano; Massimo Zeviani; Laurence A Bindoff; Patrick Yu-Wai-Man; Michael Hanna; Valerio Carelli; Robert McFarland; Kari Majamaa; Douglas M Turnbull; Jan Smeitink; Patrick F Chinnery
Journal:  Nat Rev Neurol       Date:  2013-07-02       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.